Expert consensus recommendations for managing adverse events in patients with metastatic prostate cancer treated with poly(ADP-ribose) polymerase inhibitor (PARPi) + novel hormonal therapy (NHT) combination therapy

Shore N.D., Broder M.S.,Barata P.C., Crispino T.,Fay A.P., Lloyd J., Mellado B., Matsubara N., Pfanzelter N.,Schlack K.,Sieber P.,Soares A., Dalglish H.,Niyazov A., Shaman S., Zielinski M.,Chang J.,Agarwal N.

European Urology Open Science（2023）

引用 0|浏览4

暂无评分

关键词

metastatic prostate cancer,prostate cancer,polymerase inhibitor,combination therapy,adp-ribose

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要